CA-170 has completed a phase-I trial for the treatment of patients with lymphoma or advanced solid cancers, including melanoma, (NCT02812875) showing acceptable safety and increased numbers of circulating activated CD4+and CD8+T-cells [125]. Here, CD8A is linked to melanoma.